**Senate File 470 - Introduced**

SENATE FILE 470
BY COMMITTEE ON HUMAN RESOURCES

(SUCCESSOR TO SF 282)

(COMPANION TO HF 520 BY COMMITTEE ON PUBLIC SAFETY)

## A BILL FOR

An Act relating to the medical use of cannabidiol including the scheduling of a cannabidiol investigational product approved as a prescription drug medication under federal law and including effective date provisions.

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF IOWA:

Section 1. NEW SECTION. **124.201A Cannabidiol investigational product — rules.**

1. If a cannabidiol investigational product approved as a prescription drug medication by the United States food and drug administration is eliminated from or revised in the federal schedule of controlled substances by the federal drug enforcement agency and notice of the elimination or revision is given to the board, the board shall similarly eliminate or revise the prescription drug medication in the schedule of controlled substances under this chapter. Such action by the board shall be immediately effective upon the date of publication of the final regulation containing the elimination or revision in the federal register.

2. The board shall adopt rules pursuant to chapter 17A to administer this section. The board may adopt rules on an emergency basis as provided in section 17A.4, subsection 3, and section 17A.5, subsection 2, to administer this section, and the rules shall be effective immediately upon filing unless a later date is specified in the rules. Any emergency rules adopted in accordance with this section shall also be published as a notice of intended action as provided in section 17A.4, subsection 1.

Sec. 2. REPEAL. Section 124D.8, Code 2017, is repealed.

Sec. 3. EFFECTIVE DATE. The section of this Act repealing section 124D.8, Code 2017, takes effect June 30, 2017.

EXPLANATION

**The inclusion of this explanation does not constitute agreement with the explanation's substance by the members of the general assembly.**

This bill relates to the medical use of cannabidiol, including the scheduling of a cannabidiol investigational product approved as a prescription drug medication under federal law.

The bill provides if a cannabidiol investigational product approved as a prescription drug medication by the United States food and drug administration is eliminated from or revised in

the federal schedule of controlled substances by the federal drug enforcement agency and notice of the elimination or revision is given to the board, the board of pharmacy shall similarly eliminate or revise the prescription drug medication in the schedule of controlled substances under Code chapter 124. Such action by the board shall be immediately effective upon the date of publication of the final regulation containing the elimination or revision in the federal register.

The bill provides that the board shall adopt rules pursuant to Code chapter 17A to administer the bill and may adopt emergency rules which shall be effective immediately upon filing unless a later date is specified in the rules. Any emergency rules adopted shall also be published as a notice of intended action as provided in Code section 17A.4, subsection 1.

The bill strikes the repeal of Code chapter 124D (medical cannabidiol Act) before the repeal becomes effective July 1, 2017.